NC-CLINIPACE
Clinipace , a global full-service contract research organization (CRO), expands its leadership team and launches a new brand identity to support its future growth as a midsized CRO. To better serve its clients, Clinipace is committed to taking a personal approach that focuses on service supported by top CRO talent and technologies.
Dawn Sauro joins Clinipace’s leadership team as chief development officer. In this role, she will be responsible for partnership strategies inclusive of leveraging her relationships within the clinical site community to refine and execute Clinipace’s site relationship strategy. Sauro comes to Clinipace from Sarah Cannon, where she served as president, Development Innovations. She also served in several leadership capacities at inVentiv Health, PRA Health Sciences and PPD.
Sharon Moore , M.D., MPH, MBA, brings more than a decade of experience at a top eight clinical research organization to her role as chief medical officer. In her new position, Moore will increase emphasis on patient data and the early interpretation of that data.
The appointment of Sauro and Moore increases the depth of Clinipace’s operational and therapeutic expertise and its continued investments in new therapeutic areas and analytics capabilities.
“We want to be known as a solutions provider that has a personal interest in our customers’ success,” said Jason Monteleone , CEO at Clinipace. “And, we are making the technology and talent investments to support that type of partnership with our clients.”
Clinipace’s new brand, CHALLENGE ACCEPTED, was developed in support of its commitment to a personalized approach where clients receive a level of collaboration and flexibility not possible with traditional CROs.
For more information, stop by Booth 1700 at the Drug Information Association (DIA) annual meeting, June 24–28, 2018.
About Clinipace
At Clinipace , a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180625005088/en/
Contact:
SCORR Marketing
Lea Studer, +1 402-366-1752
lea@scorrmarketing.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AZ-BLUE-YONDER29.3.2024 13:14:28 CET | Press release
Blue Yonder Announces Binding Agreement To Acquire One Network Enterprises for Approximately $839 Million To Create Multi-Enterprise Supply Chain Ecosystem
DEWA29.3.2024 13:13:28 CET | Press release
Dubai Electricity and Water Authority PJSC Shareholders Approve Payment of AED 3.1 Billion in Dividends
LIBERTEX29.3.2024 06:26:33 CET | Press release
PAN Finance Names Libertex ‘Global CFD Broker of the Year’
MIDEA-GROUP29.3.2024 02:40:30 CET | Press release
Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.
NY-DC-ADMINISTRATION28.3.2024 21:15:26 CET | Press release
DC Secretary Announces Annual Determinations Committees Outcome
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom